Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2010

bioMérieux Teams Up with Knome to Develop Next-Generation Sequencing-Based In Vitro Diagnostics

  • bioMérieux is taking a $5 million equity stake in Knome as part of the companies’ alliance to develop next-generation, sequencing-based in vitro diagnostics (IVDs) for cancer and infectious diseases. Cambridge, MA-based Knome provides human genome sequencing and analysis services.

    The agreement will give bioMérieux access to Knome’s genome analysis platform for use in the IVD market. Knome will have access to bioMérieux’ IP in the field of DNA extraction and sample preparation. Through the collaboration bioMérieux aims to develop next-generation diagnostics using its partner’s sequence analysis and bioinformatics platforms.

    bioMérieux is looking to develop molecular diagnostics based on multiplexed DNA sequencing as part of its strategic plan for the next five years. CEO, Stephane Bancel, believes that the combination of both companies’ technologies will allow the firm “to create the diagnostic tools of tomorrow.”

    Knome offers whole genome sequencing and analysis services to both biomedical researchers and families. The firm claims that it has been responsible for sequencing and analyzing more human genomes than any other company in the world. In 2007, it launched what it believed to be the first commercial whole genome sequencing and analysis service for individuals.

    In November 2009, Knome started KnomeDISCOVERY for researchers. It is designed to offer a one-stop service that covers access to a range of next-generation genome sequencing and analysis capabilities. This includes a range of whole genome and exome sequencing services together with discovery-supportive data management. Knome says that its core services are known and novel allele identification, multigenome comparative analysis, predictive functional analysis, and causation targeting.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »